Venlafaxine
Treatment for Peripheral Neuropathy
Typical Dosage: 75-225 mg daily (extended-release)
Effectiveness
75%
Safety Score
60%
Clinical Trials
5
Participants
18K
Comparative Safety Scale(Higher is safer)
Cyanideâ ī¸
Methđ
CigarettesđŦ
Chemoâĸī¸
Alcoholđē
Morphineđ
Antibioticsđ
Tylenolđ
Exerciseđ
Waterđ§
60
DangerousModerateSafe
Treatment Details
Dosage Range
75-225 mg daily (extended-release)
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$250
Side Effect Mgmt:$100
Total Annual:$550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$25,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$1,000
Cost per Remission
$4,583.33
Comparison vs Duloxetine
Cost Difference
$-50/year
Less expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Venlafaxine Outcomes
for Peripheral Neuropathy
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+55%
Remission Rate
+12%
Common Side Effects
Nausea
+25%
Insomnia
+20%
Dizziness
+15%
Increased blood pressure
+7%
Sources:
Active Clinical Trials
2 active trials recruiting for Venlafaxine in Peripheral Neuropathy
The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
NCT07361796RECRUITINGNA
832 participants
INTERVENTIONAL
Beijing, China
Started: Dec 15, 2025
Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy
NCT07795593NOT YET RECRUITINGPHASE4
600 participants
INTERVENTIONAL
Stanford, United States +22 more
Started: Sep 1, 2026
Completed Clinical Trials
3 completed trials for Venlafaxine in Peripheral Neuropathy
Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy
NCT01611155COMPLETEDNA
50 participants
INTERVENTIONAL
Rochester, United States
Started: Feb 17, 2012
The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement
NCT05023278COMPLETEDPHASE4
100 participants
INTERVENTIONAL
San Francisco, United States
Started: May 10, 2021
Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury
NCT00167856COMPLETEDNA
16 participants
INTERVENTIONAL
Miami, United States
Started: Jun 1, 2005